Editas Medicine Financials - Benzinga

Editas Medicine Inc

EDITNASDAQ

Trade with Public

Trade with Public

$2.79

-0.13-4.62%

Dern. MÀJ: Sep 23, 2:15 PM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Editas Medicine Financials

Editas Medicine (EDIT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of $(0.63) per share from

Benzinga Newsdesk

PRO
Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of $(0.43) per share from

Benzinga Newsdesk

Editas Medicine Q4 Earnings Assessment

Benzinga Insights

PRO
Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.25) by 76.19 percent. This is a 85 percent increase over losses of $(0.40) per share from the

Benzinga Newsdesk

PRO
Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from

Benzinga Newsdesk

PRO
Editas Medicine Q2 EPS $(0.63) Misses $(0.38) Estimate, Sales $3.578M Beat $1.666M Estimate

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved